logo
Share SHARE
FONT-SIZE Plus   Neg

Intrexon Files For IPO Of Up To $125 Mln

Biotechnology company Intrexon Corp. has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $125 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Germantown, Maryland based company plans to list on the New York Stock Exchange under the ticker symbol XON.

The company said in a preliminary prospectus that it plans to use the proceeds to fund continued investment in research and development platforms and its business development efforts.

Intrexon is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems

Intrexon, which was founded in 1998, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.

J.P. Morgan and Barclays are the joint bookrunners on the deal.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer Financial Protection Bureau or CFPB filed a lawsuit Wednesday against Navient, the nation's largest student loan company, alleging that it failed borrowers at at every stage of repayment. In response, Navient, in a statement, said the allegations are unfounded, and with political motivations, and rejected CFPB ultimatum to settle by Inauguration Day or be sued. Lilly is all set to acquire CoLucid Pharma for $46.50 per share in cash or approximately $960 million. Shares of Netflix Inc. (NFLX), Monday gained over 8 percent in extended trading session after the online-video streaming service reported a fourth-quarter profit that trumped analysts estimates, driven largely by higher-than-expected subscriber additions both domestically and internationally. Netflix...
comments powered by Disqus
Follow RTT